glp 1 agonist news Researchers find GLP-1 medications safe to continue before surgery in patients with diabetes and obesity Science's 2023 Breakthrough: GLP-1 Agonists

Interestingly, administration of liraglutide in mice with selective disruption of the cardiomyocyte GLP-1R ( Glp1r CM/ ) generated from MerCreMer transgenic mice expressing tamoxifen-inducible Cre driven by the -myosin heavy chain promoter, still produced robust cardioprotection and increased survival, suggesting that cardiomyocyte GLP-1R activation is not required for adaptive responses to ischemic and cardiomyopathic injury mediated by liraglutide (Ussher et al

Class 2: Alogliptin and linagliptin are targeted at specific areas: S1, S2, and sometimes S1` and S2 ` , Comparatively, linagliptin is almost eight times stronger than alogliptin [7], [8], [17], [20]

Sustained release is achieved by incorporating exendin-4 into 0.06 mm diameter biodegradable microspheres containing 50:50 poly (D,L-lactide-co-glycolide) (PLG) polymer and sucrose

What Does This Mean for Patients